
Verona’s ensifentrine will be a ‘paradigm shift in COPD treatment,’ GlobalData says
By Kevin Dunleavy
After no advances to treat chronic obstructive pulmonary disorder (COPD) in more than a decade, Verona Pharmaceuticals is set up for an FDA decision on ensifentrine on June 26. Meanwhile Sanofi and Regeneron have a PDUFA date of June 27 for Dupixent in the indication. Both are prospective add-on candidates to current therapy. (Stock photo/Getty Images)